Adaptive Biotechnologies Corporation (ADPT): Price and Financial Metrics

Adaptive Biotechnologies Corporation (ADPT): $33.64

-0.28 (-0.83%)

POWR Rating

Component Grades













Add ADPT to Watchlist
Sign Up

Industry: Biotech


of NR

in industry

ADPT Stock Price Chart Interactive Chart >

Price chart for ADPT

ADPT Price/Volume Stats

Current price $33.64 52-week high $71.25
Prev. close $33.92 52-week low $29.74
Day low $32.97 Volume 253,200
Day high $34.17 Avg. volume 792,928
50-day MA $34.79 Dividend yield N/A
200-day MA $41.84 Market Cap 4.74B

Adaptive Biotechnologies Corporation (ADPT) Company Bio

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

ADPT Latest News Stream

Event/Time News Detail
Loading, please wait...

ADPT Latest Social Stream

Loading social stream, please wait...

View Full ADPT Social Stream

Latest ADPT News From Around the Web

Below are the latest news stories about Adaptive Biotechnologies Corp that investors may wish to consider to help them evaluate ADPT as an investment opportunity.

Adaptive Biotechnologies surges 18% afterhours following EUA for COVID-19 test

The FDA late Friday granted Emergency Use Authorization (EUA) to Adaptive Biotechnologies (ADPT) for its T-Detect COVID test that determines recent or prior COVID-19 infection.Adaptive says that T-detect is the only T cell-based test that can detect the unique T-cell signature specific to SARS-CoV-2.The company claims the test correctly determined...

Seeking Alpha | March 6, 2021

Read More 'ADPT' Stories Here

ADPT Price Returns

1-mo -7.81%
3-mo -8.64%
6-mo -24.56%
1-year -32.04%
3-year N/A
5-year N/A
YTD -43.11%
2020 97.63%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1773 seconds.